NCT05357833View on ClinicalTrials.gov

Novel Imaging Markers in SPMS

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Secondary Progressive Multiple SclerosisMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis
Interventions
DRUG

Ferumoxytol infusion

Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.

DRUG

Gadoteridol

Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).

DIAGNOSTIC_TEST

MRI Brain and Cervical Spine

3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol

Trial Locations (1)

84108

University of Utah Health Imaging and Neurosciences Center, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER